You are here: Industry Insights > mRNA-1273

News List

UK’s MHRA starts rolling review of Moderna’s COVID-19 vaccine pharmatimes
October 29, 2020
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has begun the rolling review process of Moderna’s COVID-19 vaccine candidate, mRNA-1273.
Moderna signs Covid-19 vaccine supply deal with Qatar pharmaceutical-technology
October 29, 2020
Moderna has signed a supply agreement with the Ministry of Public Health of Qatar for its Covid-19 vaccine candidate, mRNA-1273.
Moderna announces supply agreement with the Ministry of Public Health to supply Qatar with mRNA vaccine against COVID-19 (mRNA-1273) worldpharmanews
October 28, 2020
Moderna, Inc., a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, announced a supply agreement with the Ministry of Public Health of Qatar for mRNA-1273 ..
Moderna completes enrollment of Phase 3 COVE study of mRNA vaccine against COVID-19 (mRNA-1273) worldpharmanews
October 23, 2020
Moderna, Inc., a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, announced that it has completed enrollment of 30,000 participants for the Phase 3 COVE...
Moderna Completes Enrollment in Phase III COVID-19 Vax Study contractpharma
October 23, 2020
Moderna, Inc. has completed enrollment of 30,000 participants for the Phase 3 COVE study of mRNA-1273, its COVID-19 vaccine candidate, being conducted in collaboration with the National Institutes of Health (NIH) and the Biomedical Advanced Research ...
EMA confirms eligibility for submission of Moderna’s COVID-19 vaccine pharmatimes
October 16, 2020
The European Medicines Agency (EMA) has confirmed that Moderna’s COVID-19 vaccine candidate mRNA-1273 is eligible for submission under the agency’s centralised procedure.
Moderna initiates rolling submission for Covid-19 vaccine pharmaceutical-technology
October 16, 2020
Moderna has initiated a rolling submission to Health Canada for its vaccine candidate against Covid-19, mRNA-1273.
Moderna publishes interim results from older adults in phase 1 study of its COVID-19 vaccine expresspharma
October 10, 2020
At the 25 µg and 100 µg dose levels, mRNA-1273 was generally well-tolerated in all age cohorts, neutralizing antibody titers and T cell responses in the 56-70 and 71+ age cohorts were consistent with those reported in younger adults.
40 per cent participants enrolled for COVID-19 vaccine trial: Moderna expresspharma
August 24, 2020
Moderna began the study of its vaccine candidate, mRNA-1273, in July and expects to complete enrollment in September.
Moderna Announces COVID-19 Vaccine Supply Agreement with U.S. Government americanpharmaceuticalreview
August 19, 2020
Moderna announced that the U.S. government has secured 100 million doses of mRNA-1273 as part of the U.S. government’s goal of securing early access to safe and effective COVID-19 vaccines for the American people.

Previous page 1 2 3 4 5 6 Next page